Insilico Medicine vs Vial
Side-by-side comparison of AI visibility scores, market position, and capabilities
Insilico Medicine (HKEX: 3696) raised $293M, posted $56.2M revenue in 2025, and inked a $2.75B Eli Lilly deal in 2026 using generative AI to discover drug targets in cancer and CNS.
About
Insilico Medicine is a clinical-stage biotechnology company founded in 2014 that leverages generative AI for drug discovery and development. Headquartered in Boston with offices in Hong Kong and New York, the company has built AI platforms utilizing deep generative models, reinforcement learning, and transformers to discover novel drug targets and generate molecular structures with desired properties. Its pipeline spans cancer, fibrosis, CNS diseases, infectious diseases, autoimmune conditions, and aging-related diseases.
Vial is a tech-enabled CRO that converts dermatology and ophthalmology clinics into research sites, handling regulatory administration, equipment provisioning, and patient recruitment; raised $77M Series B in 2022;
About
Vial is a clinical research organization (CRO) founded in 2020 by Simon Burns and Jason Wang and headquartered in San Francisco, California. The company has built a technology-enabled model for running clinical trials that differs from traditional CROs by directly partnering with clinical practices — particularly in dermatology and ophthalmology — and converting them into research sites. Vial handles the full operational burden: regulatory and IRB submissions, site staff training, clinical equipment provisioning, electronic data capture (EDC) setup, and patient recruitment and scheduling. This allows clinics with no prior research experience to participate in trials, dramatically expanding the pool of available sites and accelerating patient enrollment timelines.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.